FTC, Pharmacy Benefit Managers and Drug Prices

Pharmacy Benefit Managers Not Thrilled With FTC Report Finding Pharmacy Benefit Managers Raise Drug Prices
The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report examines the impact of PBMs (specifically CVS Caremark,
FTC report shows $7.3 billion in drug price inflation by leading pharmacy benefit managers
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.
FTC report highlights prescription drug pricing issues in Lubbock
Prescription drug prices are rising, and a new report from the Federal Trade Commission (FTC) explains why. Pharmacy benefit managers (PBM) are being blamed for driving up costs. Between 2017 and 2022,
FTC Report Highlights Prescription Drug Price Markups by PBMs
A report from the Federal Trade Commission (FTC) has determined that pharmacy benefit managers (PBMs) are linked to significant cost increases for cancer, HIV, and other critical specialty drugs.
Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by the Federal Trade Commission (FTC) on Tuesday.
US FTC finds major pharmacy benefit managers inflated drug prices for $7.3 billion gain
The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including for heart disease, cancer and HIV, at their affiliated pharmacies, the U.S.
Pharmacy benefit managers marked up drug prices by $7.3B, new reports finds
A new FTC report blames Pharmacy Benefit Managers for marking up specialty drug prices, profiting $7.3 billion from cancer and HIV treatments between 2017-2022.
FTC says Minnesota-based Optum, et al., inflate cancer drug prices 1,000%
Optum RX, CVS Caremark and Express Scripts are marking up drugs that treat cancer and multiple sclerosis by more than 1,000-percent.
pharmaphorum2d
FTC doubles down on PBM criticism in new report
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
PBMs made billions marking up specialty drugs by more than 1,000 percent: FTC
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...
FTC finds middlemen inflate specialty generic drug prices by billions of dollars
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...
Top three insurers reaped $7.3 billion through their drug middlemen's markups, FTC says
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
The FTC Finds United Health’s OptumRX Is Engaged In Widespread Price Gouging
The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...
Fierce Healthcare3d
FTC: Big 3 PBMs generated $7.3B from specialty generic drug markups
CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal ...
New legislation aims to prevent PBMs from controlling drug pricing and pharmacy ownership
The Arkansas Pharmacists Association is calling for public and legislative support for stronger regulation of Pharmacy ...
FTC Launches Inquiry of Single-Family Rental Home 'Mega Investors,' Issues PBM Report
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...